Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Levim Biotech is a Chennai, India-based biopharmaceutical company specializing in the development, manufacturing, and commercialization of biosimilars and novel biologics. Founded in 2014, the company focuses on therapeutic areas such as metabolic disorders, oncology, and acute cardiovascular diseases. Levim Biotech's commercial portfolio includes Lirafit (a biosimilar liraglutide for type 2 diabetes and obesity marketed with Glenmark), Streptolev/Icikinase (recombinant streptokinase for myocardial infarction), and Pegaspire (pegaspargase for acute lymphoblastic leukemia). Additionally, the company is developing a proprietary Gelatin-Antibody Delivery System (GADS) platform for targeted antibody-siRNA conjugates to treat resistant cancers. Levim operates a state-of-the-art cGMP manufacturing facility at Ticel Bio Park in Chennai and offers CDMO services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Levim Biotech.